Sadowitz Benjamin, Maier Kristopher G, Gahtan Vivian
Division of Vascular Surgery and Endovascular Services, SUNY Upstate Medical University, Syracuse, NY, USA.
Vasc Endovascular Surg. 2010 May;44(4):241-51. doi: 10.1177/1538574410362922.
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-reductase) inhibitors, otherwise known as statins, are currently the medical treatment of choice for hypercholesterolemia. Hypercholesterolemia is a known risk factor for cardiovascular disease, and statin therapy has led to a significant reduction in morbidity and mortality from adverse cardiac events, stroke, and peripheral arterial disease. In addition to achieving a therapeutic decrease in serum cholesterol levels, statin therapy appears to promote other effects that are independent of changes in serum cholesterol. These ''pleiotropic'' effects include attenuation of vascular inflammation, improved endothelial cell function, stabilization of atherosclerotic plaque, decreased vascular smooth muscle cell migration and proliferation, and inhibition of platelet aggregation. This article is part I of a 2-part review, and it focuses on the pleiotropic effects of statins at the cellular level.
3-羟基-3-甲基戊二酰辅酶A还原酶(HMG CoA还原酶)抑制剂,即他汀类药物,目前是高胆固醇血症的首选药物治疗方法。高胆固醇血症是已知的心血管疾病风险因素,他汀类药物治疗已显著降低了不良心脏事件、中风和外周动脉疾病的发病率和死亡率。除了使血清胆固醇水平实现治疗性降低外,他汀类药物治疗似乎还能产生其他与血清胆固醇变化无关的作用。这些“多效性”作用包括减轻血管炎症、改善内皮细胞功能、稳定动脉粥样硬化斑块、减少血管平滑肌细胞迁移和增殖以及抑制血小板聚集。本文是一篇分两部分的综述的第一部分,重点关注他汀类药物在细胞水平上的多效性作用。